|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZMYM2 |
Gene summary for ZMYM2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZMYM2 | Gene ID | 7750 |
| Gene name | zinc finger MYM-type containing 2 | |
| Gene Alias | FIM | |
| Cytomap | 13q12.11 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A0A024RDS3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7750 | ZMYM2 | CA_HPV_3 | Human | Cervix | CC | 5.59e-04 | 3.57e-02 | 0.0414 |
| 7750 | ZMYM2 | CCI_1 | Human | Cervix | CC | 1.05e-11 | 1.02e+00 | 0.528 |
| 7750 | ZMYM2 | CCI_2 | Human | Cervix | CC | 1.78e-13 | 1.41e+00 | 0.5249 |
| 7750 | ZMYM2 | CCI_3 | Human | Cervix | CC | 1.53e-12 | 1.01e+00 | 0.516 |
| 7750 | ZMYM2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.59e-16 | -4.93e-01 | 0.0155 |
| 7750 | ZMYM2 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.77e-03 | -3.45e-01 | -0.1088 |
| 7750 | ZMYM2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.75e-02 | -5.01e-01 | -0.2196 |
| 7750 | ZMYM2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.03e-06 | -5.30e-01 | -0.1207 |
| 7750 | ZMYM2 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.04e-05 | -3.42e-01 | -0.1464 |
| 7750 | ZMYM2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.11e-04 | -5.09e-01 | -0.2061 |
| 7750 | ZMYM2 | HTA11_5216_2000001011 | Human | Colorectum | SER | 2.21e-05 | -7.75e-01 | -0.1462 |
| 7750 | ZMYM2 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.03e-15 | -5.26e-01 | 0.096 |
| 7750 | ZMYM2 | HTA11_9408_2000001011 | Human | Colorectum | AD | 2.38e-04 | -8.06e-01 | 0.0451 |
| 7750 | ZMYM2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 6.30e-11 | -3.27e-01 | 0.0674 |
| 7750 | ZMYM2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.89e-03 | 6.12e-01 | 0.281 |
| 7750 | ZMYM2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.79e-09 | -3.37e-01 | 0.3005 |
| 7750 | ZMYM2 | A001-C-207 | Human | Colorectum | FAP | 4.37e-02 | -1.16e-01 | 0.1278 |
| 7750 | ZMYM2 | A015-C-203 | Human | Colorectum | FAP | 2.17e-35 | -3.40e-01 | -0.1294 |
| 7750 | ZMYM2 | A015-C-204 | Human | Colorectum | FAP | 6.87e-09 | -2.57e-01 | -0.0228 |
| 7750 | ZMYM2 | A014-C-040 | Human | Colorectum | FAP | 5.06e-10 | -5.81e-01 | -0.1184 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZMYM2 | SNV | Missense_Mutation | c.190N>A | p.Glu64Lys | p.E64K | Q9UBW7 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.991) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZMYM2 | SNV | Missense_Mutation | novel | c.1619N>A | p.Arg540Gln | p.R540Q | Q9UBW7 | protein_coding | deleterious(0.01) | benign(0.269) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZMYM2 | SNV | Missense_Mutation | c.2440C>T | p.Pro814Ser | p.P814S | Q9UBW7 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZMYM2 | SNV | Missense_Mutation | c.3371N>G | p.His1124Arg | p.H1124R | Q9UBW7 | protein_coding | tolerated(0.53) | benign(0) | TCGA-AN-A0XO-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ZMYM2 | SNV | Missense_Mutation | rs766102273 | c.1379A>G | p.Asn460Ser | p.N460S | Q9UBW7 | protein_coding | deleterious(0) | possibly_damaging(0.702) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| ZMYM2 | SNV | Missense_Mutation | c.1814N>T | p.Tyr605Phe | p.Y605F | Q9UBW7 | protein_coding | tolerated(0.26) | possibly_damaging(0.682) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZMYM2 | SNV | Missense_Mutation | c.1303N>T | p.Arg435Cys | p.R435C | Q9UBW7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A27T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| ZMYM2 | SNV | Missense_Mutation | c.1183N>C | p.Glu395Gln | p.E395Q | Q9UBW7 | protein_coding | tolerated(0.23) | probably_damaging(0.978) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ZMYM2 | SNV | Missense_Mutation | c.2353G>A | p.Gly785Arg | p.G785R | Q9UBW7 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-E9-A1RI-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| ZMYM2 | insertion | Nonsense_Mutation | novel | c.4125_4126insTTGTTGAATTAGAAACAAATGTGGTCAATAACTAGTGTTT | p.Thr1376LeufsTer4 | p.T1376Lfs*4 | Q9UBW7 | protein_coding | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |